Literature DB >> 29551391

Modelling the pathogenesis of Myotonic Dystrophy type 1 cardiac phenotype through human iPSC-derived cardiomyocytes.

Paola Spitalieri1, Rosa V Talarico1, Silvia Caioli2, Michela Murdocca1, Annalucia Serafino3, Marco Girasole4, Simone Dinarelli4, Giovanni Longo4, Sabina Pucci1, Annalisa Botta1, Giuseppe Novelli1, Cristina Zona5, Ruggiero Mango6, Federica Sangiuolo7.   

Abstract

Myotonic Dystrophy type 1 (DM1) is a multisystemic disease, autosomal dominant, caused by a CTG repeat expansion in DMPK gene. We assessed the appropriateness of patient-specific induced pluripotent stem cell-derived cardiomyocytes (CMs) as a model to recapitulate some aspects of the pathogenetic mechanism involving cardiac manifestations in DM1 patients. Once obtained in vitro, CMs have been characterized for their morphology and their functionality. CMs DM1 show intranuclear foci and transcript markers abnormally spliced respect to WT ones, as well as several irregularities in nuclear morphology, probably caused by an unbalanced lamin A/C ratio. Electrophysiological characterization evidences an abnormal profile only in CMs DM1 such that the administration of antiarrythmic drugs to these cells highlights even more the functional defect linked to the disease. Finally, Atomic Force Measurements reveal differences in the biomechanical behaviour of CMs DM1, in terms of frequencies and synchronicity of the beats. Altogether the complex phenotype described in this work, strongly reproduces some aspects of the human DM1 cardiac phenotype. Therefore, the present study provides an in vitro model suggesting novel insights into the mechanisms leading to the development of arrhythmogenesis and dilatative cardiomyopathy to consider when approaching to DM1 patients, especially for the risk assessment of sudden cardiac death (SCD). These data could be also useful in identifying novel biomarkers effective in clinical settings and patient-tailored therapies.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiarrhytmic drugs; Cardiomyocytes; Electrophysiological analysis; Human induced pluripotent stem cells; Myotonic Dystrophy type 1 (DM1)

Mesh:

Substances:

Year:  2018        PMID: 29551391     DOI: 10.1016/j.yjmcc.2018.03.012

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

Review 1.  Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing.

Authors:  Mariapaola Izzo; Jonathan Battistini; Claudia Provenzano; Fabio Martelli; Beatrice Cardinali; Germana Falcone
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

Review 2.  A Review of the Effect of a Nanostructured Thin Film Formed by Titanium Carbide and Titanium Oxides Clustered around Carbon in Graphitic Form on Osseointegration.

Authors:  Roberto Scandurra; Anna Scotto d'Abusco; Giovanni Longo
Journal:  Nanomaterials (Basel)       Date:  2020-06-24       Impact factor: 5.076

3.  Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes-a systematic review.

Authors:  Thomas Eschenhagen; Lucie Carrier
Journal:  Pflugers Arch       Date:  2018-10-15       Impact factor: 3.657

4.  iPSC-derived cardiomyocytes from patients with myotonic dystrophy type 1 have abnormal ion channel functions and slower conduction velocities.

Authors:  Hugo Poulin; Aurélie Mercier; Mohammed Djemai; Valérie Pouliot; Isabelle Deschenes; Mohamed Boutjdir; Jack Puymirat; Mohamed Chahine
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

5.  Two Different Therapeutic Approaches for SARS-CoV-2 in hiPSCs-Derived Lung Organoids.

Authors:  Paola Spitalieri; Federica Centofanti; Michela Murdocca; Maria Giovanna Scioli; Andrea Latini; Silvia Di Cesare; Gennaro Citro; Antonio Rossi; Augusto Orlandi; Shane Miersch; Sachdev S Sidhu; Pier Paolo Pandolfi; Annalisa Botta; Federica Sangiuolo; Giuseppe Novelli
Journal:  Cells       Date:  2022-04-05       Impact factor: 6.600

6.  Comprehensive transcriptome-wide analysis of spliceopathy correction of myotonic dystrophy using CRISPR-Cas9 in iPSCs-derived cardiomyocytes.

Authors:  Sumitava Dastidar; Debanjana Majumdar; Jaitip Tipanee; Kshitiz Singh; Arnaud F Klein; Denis Furling; Marinee K Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2021-08-08       Impact factor: 11.454

7.  Volatile compounds emission from teratogenic human pluripotent stem cells observed during their differentiation in vivo.

Authors:  Rosamaria Capuano; Paola Spitalieri; Rosa Valentina Talarico; Alexandro Catini; Ana Carolina Domakoski; Eugenio Martinelli; Maria Giovanna Scioli; Augusto Orlandi; Rosella Cicconi; Roberto Paolesse; Giuseppe Novelli; Corrado Di Natale; Federica Sangiuolo
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

8.  Generation and Neuronal Differentiation of hiPSCs From Patients With Myotonic Dystrophy Type 2.

Authors:  Paola Spitalieri; Rosa V Talarico; Michela Murdocca; Luana Fontana; Marzia Marcaurelio; Elena Campione; Roberto Massa; Giovanni Meola; Annalucia Serafino; Giuseppe Novelli; Federica Sangiuolo; Annalisa Botta
Journal:  Front Physiol       Date:  2018-07-27       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.